Prognostic Value of TTF-2 and FOXE1 Alterations in Papillary Thyroid Carcinoma: Linking Immunohistochemistry to Genetic Insights


Aras F., Çam F. S., Tan A., Mavili H. S.

Avrupa Nükleer Tıp Kongresi (EANM), Vienna, Avusturya, 17 - 21 Ekim 2026, cilt.4, sa.247, ss.93-94, (Tam Metin Bildiri)

  • Yayın Türü: Bildiri / Tam Metin Bildiri
  • Cilt numarası: 4
  • Doi Numarası: 10.1016/s3051-2913(26)00285-5
  • Basıldığı Şehir: Vienna
  • Basıldığı Ülke: Avusturya
  • Sayfa Sayıları: ss.93-94
  • Manisa Celal Bayar Üniversitesi Adresli: Evet

Özet

Aim/Introduction: Papillary thyroid carcinoma (PTC) is the most common differentiated thyroid cancer, generally associated with favorable prognosis. However, a subset of patients develops aggressive disease with metastatic spread. Thyroid transcription factors TTF-1 (NKX2-1) and TTF-2 (FOXE1) are critical regulators of thyroid differentiation and may serve as diagnostic or prognostic markers. This study aimed to investigate immunohistochemical expression of TTF-1 and TTF-2, as well as sequence variations in FOXE1 and NKX2-1, in metastatic and nonmetastatic PTC patients treated with radioactive iodine. Materials and Methods: A total of 60 patients with PTC (31 non-metastatic and 29 metastatic) who underwent thyroidectomy followed by radioactive iodine ablation were retrospectively analyzed. Immunohistochemistry for TTF-1 and TTF-2 was performed and staining intensities were quantified. Targeted sequencing was conducted to detect FOXE1 and NKX2-1 variants. Associations between molecular findings and clinicopathological parameters were assessed using appropriate statistical tests. Results: TTF-1 expression did not significantly differ between metastatic and non-metastatic groups (p > 0.05). In contrast, TTF-2 expression was significantly higher in metastatic cases, with strong positivity (+3) observed more frequently compared with non-metastatic patients (p = 0.046). Negative TTF-2 staining was more common in non-metastatic cases (p = 0.011). In-frame deletions in the FOXE1 gene, resulting in the loss of alanine residues without frameshift, were detected in all samples from both groups, while NKX2-1 variants in the 5′-UTR were observed in a high proportion of patients but showed no significant association with metastasis. Conclusion: TTF-2 expression is significantly associated with metastatic disease in PTC and may represent a useful prognostic biomarker, whereas TTF-1 shows limited prognostic value. The universal presence of FOXE1 deletions suggests a possible structural alteration with biological relevance, although not directly linked to metastatic status. Integrating immunohistochemical and genetic markers may enhance individualized risk stratification in PTC. References: 1.Yamaguchi T, Hosono Y, Yanagisawa K, Takahashi T (2013) NKX2-1/TTF-1: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. Cancer Cell 23 (6):718-723. doi:10.1016/j.ccr.2013.04.0022. Kondo T, Nakazawa T, Ma D, Niu D, Mochizuki K, Kawasaki T, Nakamura N, Yamane T, Kobayashi M, Katoh R (2009) Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. Lab Invest 89 (7):791- 799. doi:10.1038/labinvest.2009.50 3. Ito Y, Furuya F, Taki K, Suzuki H, Shimura H (2021) NKX2-1 re-expression induces EANM Innovation (2026) S94 cell death through apoptosis and necrosis in dedifferentiated thyroid carcinoma cells. PLoS One 16 (11):e0259558. doi:10.1371/journal.pone.0259558.